GlassScriptPhysician profile
Marcus W Lum
NPI 1003839242
$6,052.95
in general payments reported to CMS, 2019-2025
36 companies · $954 in 2025
The $954 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $174 · 2021: $499 · 2022: $986 · 2023: $1,366 · 2024: $1,012 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.27 |
| Education | $176.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $973.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $709.10 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $487.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $476.43 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $347.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $328.41 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Janssen Pharmaceuticals, INC | $303.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.12 | 2019-2025 | Jardiance |
| Abbvie INC. | $261.78 | 2021-2025 | |
| Pfizer INC. | $246.41 | 2019-2025 | |
| Amgen INC. | $237.22 | 2019-2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $184.78 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $175.60 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $158.84 | 2019-2025 | |
| Almatica Pharma LLC | $113.56 | 2022-2023 | Loreev Xr, Sertraline Hcl |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Lum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.